Literature DB >> 26582647

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

M S Zabriskie1, C A Eide2,3, D Yan1, N A Vellore1, A D Pomicter1, S L Savage2, B J Druker2,3, M W Deininger1,4, T O'Hare1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26582647      PMCID： PMC4873472          DOI： 10.1038/leu.2015.318

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Reversing Halt, FDA reauthorizes sale of ponatinib.

Authors:  Andrew J Roth
Journal:  Am J Manag Care       Date:  2014-02       Impact factor: 2.229

2.  Ariad suspends ponatinib sales.

Authors: 
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

3.  Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Authors:  Tea Pemovska; Eric Johnson; Mika Kontro; Gretchen A Repasky; Jeffrey Chen; Peter Wells; Ciarán N Cronin; Michele McTigue; Olli Kallioniemi; Kimmo Porkka; Brion W Murray; Krister Wennerberg
Journal:  Nature       Date:  2015-02-09       Impact factor: 49.962

4.  BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Authors:  Matthew S Zabriskie; Christopher A Eide; Srinivas K Tantravahi; Nadeem A Vellore; Johanna Estrada; Franck E Nicolini; Hanna J Khoury; Richard A Larson; Marina Konopleva; Jorge E Cortes; Hagop Kantarjian; Elias J Jabbour; Steven M Kornblau; Jeffrey H Lipton; Delphine Rea; Leif Stenke; Gisela Barbany; Thoralf Lange; Juan-Carlos Hernández-Boluda; Gert J Ossenkoppele; Richard D Press; Charles Chuah; Stuart L Goldberg; Meir Wetzler; Francois-Xavier Mahon; Gabriel Etienne; Michele Baccarani; Simona Soverini; Gianantonio Rosti; Philippe Rousselot; Ran Friedman; Marie Deininger; Kimberly R Reynolds; William L Heaton; Anna M Eiring; Anthony D Pomicter; Jamshid S Khorashad; Todd W Kelley; Riccardo Baron; Brian J Druker; Michael W Deininger; Thomas O'Hare
Journal:  Cancer Cell       Date:  2014-08-14       Impact factor: 31.743

5.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

Review 6.  Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.

Authors:  Sergio Bracarda; Daniel Castellano; Giuseppe Procopio; Juan M Sepúlveda; Michele Sisani; Elena Verzoni; Manuela Schmidinger
Journal:  Expert Opin Drug Saf       Date:  2014-04       Impact factor: 4.250

Review 7.  Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.

Authors:  Javid J Moslehi; Michael Deininger
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

Review 8.  Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.

Authors:  Marine Gross-Goupil; Louis François; Amandine Quivy; Alain Ravaud
Journal:  Clin Med Insights Oncol       Date:  2013-10-29

Review 9.  Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma.

Authors:  Orvar Gunnarsson; Nicklas R Pfanzelter; Roger B Cohen; Stephen M Keefe
Journal:  Cancer Manag Res       Date:  2015-02-11       Impact factor: 3.989

10.  Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.

Authors:  Brian I Rini; David I Quinn; Michael Baum; Laura S Wood; Jamal Tarazi; Brad Rosbrook; Lillian Shahied Arruda; Laura Cisar; W Gregory Roberts; Sinil Kim; Robert J Motzer
Journal:  Target Oncol       Date:  2014-03-05       Impact factor: 4.493
View more
  6 in total

1.  BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.

Authors:  Konstantin Byrgazov; Chantal Blanche Lucini; Peter Valent; Oliver Hantschel; Thomas Lion
Journal:  Haematologica       Date:  2017-10-05       Impact factor: 9.941

Review 2.  Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Authors:  Ami B Patel; Thomas O'Hare; Michael W Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2017-08       Impact factor: 3.722

3.  The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.

Authors:  H Jonathan G Lindström; Ran Friedman
Journal:  BMC Cancer       Date:  2020-05-07       Impact factor: 4.430

4.  Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.

Authors:  Valentina Giudice; Andrea Ghelli Luserna di Rorà; Bianca Serio; Roberto Guariglia; Maria Benedetta Giannini; Anna Ferrari; Giorgia Simonetti; Carmine Selleri; Giovanni Martinelli
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

5.  INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.

Authors:  Giovanni Martinelli; Cristina Papayannidis; Alfonso Piciocchi; Valentina Robustelli; Simona Soverini; Carolina Terragna; Giovanni Marconi; Roberto M Lemoli; Fabio Guolo; Antonella Fornaro; Monia Lunghi; Paolo de Fabritiis; Anna Candoni; Carmine Selleri; Federico Simonetti; Monica Bocchia; Antonella Vitale; Luca Frison; Alessandra Tedeschi; Antonio Cuneo; Massimiliano Bonifacio; Maria Paola Martelli; Stefano D'Ardia; Silvia Trappolini; Patrizia Tosi; Piero Galieni; Francesco Fabbiano; Maria Chiara Abbenante; Muriel Granier; Zhaoyin Zhu; Mingyue Wang; Chiara Sartor; Stefania Paolini; Michele Cavo; Robin Foà; Paola Fazi; Marco Vignetti; Michele Baccarani
Journal:  Blood Adv       Date:  2022-03-22

Review 6.  Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

Authors:  Vinayak Palve; Yi Liao; Lily L Remsing Rix; Uwe Rix
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.